GABA-B pathway

Seaside Therapeutics was the first to identify GABA-B as a drug target in treating fragile X syndrome and autism. Recent studies show that there is deficient inhibitory neurotransmission in fragile X syndrome and autism, and that STX209, a GABA-B agonist, has the potential to normalize this deficiency. Furthermore, modulation of the GABA-B pathway may provide additional therapeutic benefits by indirectly reducing activation of the mGluR5 pathway.